CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 86 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q2 2021. The put-call ratio across all filers is 0.25 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,538,021 | -30.7% | 116,263 | +0.9% | 0.02% | -34.4% |
| Q2 2023 | $3,664,719 | +45.6% | 115,279 | +11.7% | 0.03% | +45.5% |
| Q1 2023 | $2,517,292 | -24.8% | 103,210 | -2.7% | 0.02% | -26.7% |
| Q4 2022 | $3,345,322 | +39.3% | 106,066 | +24.8% | 0.03% | +30.4% |
| Q3 2022 | $2,401,000 | +3.2% | 84,970 | -3.4% | 0.02% | 0.0% |
| Q2 2022 | $2,326,000 | -56.3% | 87,969 | -42.2% | 0.02% | -60.3% |
| Q1 2022 | $5,326,000 | -3.6% | 152,115 | -10.7% | 0.06% | -6.5% |
| Q4 2021 | $5,524,000 | +5.5% | 170,399 | -4.0% | 0.06% | +24.0% |
| Q3 2021 | $5,238,000 | +22.4% | 177,565 | +6.3% | 0.05% | +31.6% |
| Q2 2021 | $4,278,000 | – | 166,983 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,199,729 | $1,314,160,084 | 42.08% |
| Perceptive Advisors | 10,088,385 | $220,229,445 | 7.35% |
| Finepoint Capital LP | 563,345 | $12,297,821 | 6.12% |
| Affinity Asset Advisors, LLC | 685,061 | $14,954,882 | 4.21% |
| Paradigm Biocapital Advisors LP | 2,532,972 | $55,294,779 | 3.75% |
| Logos Global Management LP | 700,000 | $15,281,000 | 2.04% |
| Artal Group S.A. | 1,638,858 | $35,776 | 1.53% |
| Rock Springs Capital Management LP | 2,529,116 | $55,210,602 | 1.48% |
| GREAT POINT PARTNERS LLC | 215,000 | $4,693,450 | 0.86% |
| Frazier Life Sciences Management, L.P. | 393,000 | $8,579,190 | 0.57% |